CX Institutional Sells 14,125 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• CX Institutional cut its Thermo Fisher Scientific stake by 72.1% in the third quarter, selling 14,125 shares and retaining 5,462 shares valued at approximately $3.69 million. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03 and revenue of $11.99 billion, exceeding analyst expectations, while revenue rose 10.5% year over year. The company issued fiscal 2026 EPS guidance of $24.93–$25.33.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and a $628.78 price target, although Citigroup downgraded the stock to “underperform.” Thermo Fisher also declared a quarterly dividend of $0.47 per share.

CX Institutional decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 72.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,462 shares of the medical research company's stock after selling 14,125 shares during the period. CX Institutional's holdings in Thermo Fisher Scientific were worth $3,687,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Kilter Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 2nd quarter worth about $25,000. Legacy Wealth Managment LLC ID boosted its holdings in shares of Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after buying an additional 22 shares during the period. Allied Private Wealth LLC acquired a new stake in Thermo Fisher Scientific during the second quarter worth approximately $26,000. MBM Wealth Consultants LLC bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $29,000. Finally, Pingora Partners LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $30,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 0.5%

TMO stock opened at $655.49 on Friday. The company's 50 day moving average is $618.62 and its 200 day moving average is $534.71. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock has a market cap of $242.37 billion, a price-to-earnings ratio of 35.26, a price-to-earnings-growth ratio of 2.73 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $683.63.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm's revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 10.11%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Citigroup downgraded shares of Thermo Fisher Scientific from a "buy" rating to an "underperform" rating in a research report on Wednesday, September 9th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $720.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, September 25th. UBS Group upgraded shares of Thermo Fisher Scientific from a "neutral" rating to a "buy" rating and increased their price target for the stock from $540.00 to $730.00 in a research report on Tuesday, September 8th. Scotiabank assumed coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They set an "outperform" rating for the company. Finally, Weiss Ratings raised Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 28th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of "Moderate Buy" and a consensus price target of $628.78.

Insider Activity

In other news, CEO Marc Casper sold 275 shares of the company's stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at approximately $77,707,171.25. This represents a 0.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa Britt sold 11,440 shares of the company's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total value of $7,014,092.80. Following the transaction, the vice president directly owned 14,784 shares of the company's stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 73,768 shares of company stock worth $44,122,820 in the last quarter. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.